HIGHLIGHTS
- who: Tingting Tan et al. from the United States University of Verona, Italy have published the research: Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma, in the Journal: (JOURNAL) of September/17,/2021
SUMMARY
Renal cell carcinoma (RCC) is a rapidly progressing malignant tumor of urinary system. The combination of lenvatinib plus pembrolizumab even showed antitumor activity for patients with previously treated metastatic renal cell carcinoma. Previous studies in mouse tumor isograft models have demonstrated the immunomodulatory . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.